The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Open accessAbstract
Purpose: Since treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-line treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of individual patient data was performed to compare the two treatments. Patients and Methods: A systematic review identified randomized trials comparing cisplatin with carboplatin in the first-line treatment of SCLC. Individual patient data were obtained from coordinating centers of all eligible trials. The primary end point was overall survival (OS). All statistical analyses were stratified by trial. Secondary end points were progression-free survival (PFS), objective response rate (ORR), and treatment toxicity. OS and PFS curves were compared by using the log-rank test. ORR was compared by using the Mantel-Haenszel test. Results: Four eligible trials with 663 patients (328 assigned to cisplatin and 335 to carboplatin) were included in the analysis. Median OS was 9.6 months for cisplatin and 9.4 months for carboplatin (hazard ratio [HR], 1.08; 95% CI, 0.92 to 1.27; P = .37). There was no evidence of treatment difference between the cisplatin and carboplatin arms according to sex, stage, performance status, or age. Median PFS was 5.5 and 5.3 months for cisplatin and carboplatin, respectively (HR, 1.10; 95% CI, 0.94 to 1.29; P = .25). ORR was 67.1% and 66.0%, respectively (relative risk, 0.98; 95% CI, 0.84 to 1.16; P = .83). Toxicity profile was significantly different for each of the arms: hematologic toxicity was higher with carboplatin, and nonhematologic toxicity was higher with cisplatin. Conclusion: Our meta-analysis of individual patient data suggests no differences in efficacy between cisplatin and carboplatin in the first-line treatment of SCLC, but there are differences in the toxicity profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,845
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Thoracic Cancer · doi:10.1111/j.1759-7714.2010.00016.x · Cited by 884
Cancer: Principles and Practice of Oncology
CLAUDINO, W. M., & BIGANZOLI, L. (2007) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2006.00680.x · Cited by 855
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk196 · Cited by 612
Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.109 · Cited by 364
Carboplatin versus cisplatin in solid tumors: An analysis of the literature
Lokich, J., & Anderson, N. (1998) · Annals of Oncology · doi:10.1023/a:1008215213739 · Cited by 304
Skarlos, D. V., Samantas, E., Kosmidis, P., Fountzilas, G., Angelidou, M., Palamidas, P. H., Mylonakis, N., Provata, A., Papadakis, E., Klouvas, G., et al. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058931 · Cited by 274
Self-citationManagement of Small Cell Lung Cancer
Simon, G. R., & Turrisi, A. (2007) · Chest · doi:10.1378/chest.07-1385 · Cited by 226
on Behalf of the Japan Clinical Oncology Group (JCOG)-Lung Cancer Study Group, Okamoto, H., Watanabe, K., Kunikane, H., Yokoyama, A., Kudoh, S., Asakawa, T., Shibata, T., Kunitoh, H., Tamura, T., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603810 · Cited by 213
Self-citationInvestigating heterogeneity in an individual patient data meta-analysis of time to event outcomes
Smith, C. T., Williamson, P. R., & Marson, A. G. (2005) · Statistics in Medicine · doi:10.1002/sim.2050 · Cited by 173
Meta-Analyses Based on Abstracted Data: A Step in the Right Direction, but Only a First Step
Piedbois, P., & Buyse, M. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.924 · Cited by 94
Meta-analyses of randomised clinical trials in oncology
Pignon, J., & Hill, C. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00453-3 · Cited by 94
Kosmidis, P., Samantas, E., Fountzilas, G., Pavlidis, N., Apostolopoulou, F., & Skarlos, D.-V. (1994) · PubMed · Cited by 88
Self-citationSocinski, M. A., Weissman, C., Hart, L. L., Beck, J. T., Choksi, J. K., Hanson, J. P., Prager, D., Monberg, M., Ye, Z., & Obasaju, C. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.7016 · Cited by 83
1st ESMO Consensus Conference in lung cancer; Lugano 2010: Small-cell lung cancer
Stahel, R. A., Thatcher, N., Früh, M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr313 · Cited by 69
Self-citationLee, S. M., James, L. E., Qian, W., Spiro, S. G., Eisen, T. G., Gower, N. H., Ferry, D., Gilligan, D., Harper, P., Prendiville, J., et al. (2008) · Thorax · doi:10.1136/thx.2007.093872 · Cited by 66
Self-citationExact and asymptotic tests for homogeneity in several 2×2 tables
dos Reis, I. M., Hirji, K. F., & Afifi, A. A. (1999) · Statistics in Medicine · Cited by 35
Monnet, I., Chariot, P., Quoix, É., Ruffiè, P., Voisin, S., Chevalier, T. L., Saltiel, J.-C., & de Crémoux, H. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058101 · Cited by 8
Cited by
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Dingemans, A.-M. C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L. E., Lantuejoul, S., Peters, S., Reguart, N., Rudin, C. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.207 · Cited by 626
Self-citationFrüh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., & Felip, E. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt178 · Cited by 613
Self-citationOtt, P. A., Elez, E., Hiret, S., Kim, D.-W., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 521
Cheng, Y., Han, L., Wu, L., Chen, J., Sun, H., Wen, G., Ji, Y., Dvorkin, M., Shi, J., Pan, Z., et al. (2022) · JAMA · doi:10.1001/jama.2022.16464 · Cited by 492
Metadata
- Authors
- Rossi, A., Di Maio, M., Chiodini, P., Rudd, R. M., Okamoto, H., Skarlos, D. V., Früh, M., Qian, W., Tamura, T., Samantas, E., Shibata, T., Perrone, F., Gallo, C., Gridelli, C., Martelli, O., & Lee, S.-M.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-05-10
- Volume
- 30
- Issue
- 14
- Pages
- 1692-1698
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2101156795
- Cited by
- 570
- References
- 22
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.